Antihistamines in Psoriasis.

Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the management of itch in psoriasis. The literature search included peer-reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) until January 2021 and by reference lists of respective articles. J Drugs Dermatol. 2021;20(8):844-847. doi:10.36849/JDD.5966.

Citation

Swathi Shivakumar, Simon M Mueller, Paul S Yamauchi, Jeffrey M Weinberg, Leon Kircik, Jacek C Szepietowski, Mohamad Goldust. Antihistamines in Psoriasis. Journal of drugs in dermatology : JDD. 2021 Aug 01;20(8):844-847

PMID: 34397204

search → result